tradingkey.logo
tradingkey.logo

HUTCHMED (China) Ltd

HCM
13.810USD
-0.350-2.47%
종가 03/27, 16:00ET시세는 15분 지연됩니다
2.41B시가총액
25.54P/E TTM

HUTCHMED (China) Ltd

13.810
-0.350-2.47%

자세한 내용은 HUTCHMED (China) Ltd 회사

HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.

HUTCHMED (China) Ltd 정보

종목 코드 HCM
회사 이름HUTCHMED (China) Ltd
상장일May 19, 2006
CEOCheng (Chig Fung)
직원 수1811
유형Depository Receipt
회계 연도 종료May 19
주소48th Floor, Cheung Kong Center, 2 Queen's Road Central
도시
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가Hong Kong
우편 번호- -
전화85221281188
웹사이트https://www.hutch-med.com/
종목 코드 HCM
상장일May 19, 2006
CEOCheng (Chig Fung)

HUTCHMED (China) Ltd의 회사 임원진

이름
이름/직위
직위
주식 보유
변동
Dr. Renu Bhatia
Dr. Renu Bhatia
Independent Non-Executive Director
Independent Non-Executive Director
16.00K
--
Ms. Edith Shih
Ms. Edith Shih
Non-Executive Director, Company Secretary
Non-Executive Director, Company Secretary
--
--
Mr. Chig Fung (Johnny) Cheng
Mr. Chig Fung (Johnny) Cheng
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
--
--
Dr. Dan Eldar, Ph.D.
Dr. Dan Eldar, Ph.D.
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Dr. Weiguo Su, Ph.D.
Dr. Weiguo Su, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Prof. Shu Kam (Tony) Mok
Prof. Shu Kam (Tony) Mok
Senior Lead Non-Executive Independent Director
Senior Lead Non-Executive Independent Director
--
--
Dr. Qingmei (May) Wang, Ph.D.
Dr. Qingmei (May) Wang, Ph.D.
Senior Vice President - Business Development and Strategic Alliances
Senior Vice President - Business Development and Strategic Alliances
--
--
Dr. Zhenping Wu, Ph.D.
Dr. Zhenping Wu, Ph.D.
Executive Vice President - Pharmaceutical Sciences and Manufacturing
Executive Vice President - Pharmaceutical Sciences and Manufacturing
--
--
Mr. Kin Hung (Mark) Lee
Mr. Kin Hung (Mark) Lee
Senior Vice President - Corporate Management and Communications
Senior Vice President - Corporate Management and Communications
--
--
Mr. Charles George Rupert Nixon
Mr. Charles George Rupert Nixon
Group General Counsel
Group General Counsel
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Renu Bhatia
Dr. Renu Bhatia
Independent Non-Executive Director
Independent Non-Executive Director
16.00K
--
Ms. Edith Shih
Ms. Edith Shih
Non-Executive Director, Company Secretary
Non-Executive Director, Company Secretary
--
--
Mr. Chig Fung (Johnny) Cheng
Mr. Chig Fung (Johnny) Cheng
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
--
--
Dr. Dan Eldar, Ph.D.
Dr. Dan Eldar, Ph.D.
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Dr. Weiguo Su, Ph.D.
Dr. Weiguo Su, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Prof. Shu Kam (Tony) Mok
Prof. Shu Kam (Tony) Mok
Senior Lead Non-Executive Independent Director
Senior Lead Non-Executive Independent Director
--
--

수익 분석

통화: USD마지막 업데이트: Tue, Jan 6
통화: USD마지막 업데이트: Tue, Jan 6
FY2024
FY2023
FY2022
FY2021
FY2020
기업이 아직 관련 데이터를 공개하지 않았습니다.
지역별USD
이름
수익
비율
PRC
630.20M
0.00%
Unallocated
0.00
0.00%
사업별
지역별
기업이 아직 관련 데이터를 공개하지 않았습니다.

주식 보유 통계

마지막 업데이트: Sun, Mar 22
마지막 업데이트: Sun, Mar 22
주주
주주 유형
주주
주주
비율
Schroder Investment Management (Singapore) Ltd.
0.93%
Allianz Global Investors Asia Pacific Limited
0.49%
Schroder Investment Management (Hong Kong) Ltd.
0.37%
State Street Investment Management (US)
0.18%
AIA Group Ltd
0.18%
기타
97.83%
주주
주주
비율
Schroder Investment Management (Singapore) Ltd.
0.93%
Allianz Global Investors Asia Pacific Limited
0.49%
Schroder Investment Management (Hong Kong) Ltd.
0.37%
State Street Investment Management (US)
0.18%
AIA Group Ltd
0.18%
기타
97.83%
주주 유형
주주
비율
Investment Advisor/Hedge Fund
2.22%
Investment Advisor
0.61%
Hedge Fund
0.11%
Research Firm
0.09%
Bank and Trust
0.03%
기타
96.93%

기관 주식 보유

마지막 업데이트: Thu, Jan 1
마지막 업데이트: Thu, Jan 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
143
5.83M
3.34%
-5.83M
2025Q3
144
6.22M
3.56%
-5.80M
2025Q2
160
6.97M
3.99%
-6.31M
2025Q1
166
6.98M
4.00%
-6.73M
2024Q4
187
7.28M
4.18%
-8.01M
2024Q3
259
7.73M
4.44%
-16.35M
2024Q2
280
9.29M
5.33%
-17.79M
2024Q1
306
15.01M
8.61%
-19.39M
2023Q4
327
16.63M
9.55%
-27.28M
2023Q3
339
25.00M
14.36%
-20.50M
더 보기

주주 활동

이름
보유 주식
비율
변동
Chg %
날짜
Schroder Investment Management (Singapore) Ltd.
1.69M
0.97%
-84.85K
-4.78%
Sep 30, 2025
Allianz Global Investors Asia Pacific Limited
863.00K
0.49%
-15.73K
-1.79%
Sep 30, 2025
Schroder Investment Management (Hong Kong) Ltd.
778.26K
0.45%
-27.37K
-3.40%
Sep 30, 2025
State Street Investment Management (US)
317.50K
0.18%
-11.29K
-3.43%
Sep 30, 2025
AIA Group Ltd
315.44K
0.18%
--
--
Sep 30, 2025
M&G Investment Management Ltd.
204.43K
0.12%
-55.19K
-21.26%
Sep 30, 2025
Amundi Asset Management, SAS
223.33K
0.13%
+65.90K
+41.86%
Sep 30, 2025
Renaissance Technologies LLC
131.00K
0.08%
+2.00K
+1.55%
Sep 30, 2025
Jane Street Capital, L.L.C.
340.34K
0.2%
+164.38K
+93.42%
Sep 30, 2025
Saint Olive Gestion
100.00K
0.06%
--
--
Sep 30, 2025
더 보기

관련 ETF

마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
Tema Oncology ETF
0.78%
National Security Emerging Markets Index ETF
0.35%
Invesco Nasdaq Biotechnology ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.05%
DFA Dimensional Emerging Markets Core Equity 2 ETF
0%
DFA Dimensional Em Mkts Sustainability Core 1 ETF
0%
ActivePassive International Equity ETF
0%
SPDR Portfolio Developed World ex-US ETF
0%
Tema Oncology ETF
비율0.78%
National Security Emerging Markets Index ETF
비율0.35%
Invesco Nasdaq Biotechnology ETF
비율0.05%
ProShares Ultra Nasdaq Biotechnology
비율0.05%
DFA Dimensional Emerging Markets Core Equity 2 ETF
비율0%
DFA Dimensional Em Mkts Sustainability Core 1 ETF
비율0%
ActivePassive International Equity ETF
비율0%
SPDR Portfolio Developed World ex-US ETF
비율0%

주식 배당금

지난 5년 동안 총 0.00 USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음

주식 분할

날짜
배당락일
유형
비율
데이터 없음
날짜
배당락일
유형
비율
데이터 없음
KeyAI